Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: impurity N-nitrosoirbesartan detected in API
| Brand name | IRBESARTAN |
| Generic name | IRBESARTAN |
| Active ingredient(s) | IRBESARTAN |
| Distributed by / for | Lupin Pharmaceuticals Inc. |
| NDC | 68180-412-06 |
| Full product label | Irbesartan Tablets USP, 300 mg a) 30 count (NDC 68180-412-06) and b) 90 count NDC# 68180-412-09) bottles, Rx only |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | Product was distributed to major distributors who may have further distributed the product nationwide. |
| Quantity | 119,544 bottles |
| Recall initiated | 2021-10-12 |
| Report date | 2021-11-10 |
| Recall completed | 2023-01-30 |
| Recall number | D-0088-2022 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗